Off-target ACE2 ligands : Possible therapeutic option for CoVid-19?
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:86 |
|---|---|
| Enthalten in: |
British journal of clinical pharmacology - 86(2020), 6 vom: 01. Juni, Seite 1178-1179 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Brogi, Simone [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.06.2020 Date Revised 18.12.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bcp.14343 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309426944 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309426944 | ||
| 003 | DE-627 | ||
| 005 | 20231225133903.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bcp.14343 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1031.xml |
| 035 | |a (DE-627)NLM309426944 | ||
| 035 | |a (NLM)32359080 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Brogi, Simone |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Off-target ACE2 ligands |b Possible therapeutic option for CoVid-19? |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.06.2020 | ||
| 500 | |a Date Revised 18.12.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a CoVid-19 | |
| 650 | 4 | |a SARS-Cov-2 | |
| 650 | 4 | |a betacoronavirus | |
| 650 | 4 | |a human angiotensin-converting enzyme 2 (ACE2) | |
| 650 | 4 | |a repurposing | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Ligands |2 NLM | |
| 650 | 7 | |a Peptidyl-Dipeptidase A |2 NLM | |
| 650 | 7 | |a EC 3.4.15.1 |2 NLM | |
| 650 | 7 | |a ACE2 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme 2 |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 700 | 1 | |a Calderone, Vincenzo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of clinical pharmacology |d 1974 |g 86(2020), 6 vom: 01. Juni, Seite 1178-1179 |w (DE-627)NLM000097799 |x 1365-2125 |7 nnns |
| 773 | 1 | 8 | |g volume:86 |g year:2020 |g number:6 |g day:01 |g month:06 |g pages:1178-1179 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bcp.14343 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 86 |j 2020 |e 6 |b 01 |c 06 |h 1178-1179 | ||